Sangamo Therapeutics, Inc.
NEWS
Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Sangamo and Pfizer will use the company’s ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD.
A look at a few biotechs which should outperform the market in 2018.
Biotech stocks rocked in 2017, at least a lot of them did.
In an overall good year for pharma and biotech sectors, there have been some standouts.
Barely a week after announcing it was moving into a new corporate headquarters, Sangamo announced it has dosed the first patient in its Phase I/II gene therapy trial.
Sangamo is moving its corporate headquarters to a new site at Oyster Point in Brisbane, CA.
JOBS
IN THE PRESS